Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO, October 26, 2021--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") and Nippon Kayaku Co., Ltd. (TOKYO: 4272...